BCL2L14

Across TCGA pan-cancer cohorts, BCL2L14 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of BCL2L14’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where BCL2L14 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types BCL2L14 is over-expressed in tumor, although a few such as COAD show the opposite, repressed pattern.

LUAD, HNSC, and LSCC are the cancer types where BCL2L14 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BCL2L14 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	III,IV	+0.618	<.001	7	view →
HNSC	All	All	+0.690	.036	4	view →
LSCC	All	All	+0.437	<.001	4	view →
COAD	Female	IV	−0.275	.038	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

BCL2L14–LUAD

Open the LUAD breakdown →